University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis

Completed

Conditions: Chronic Hepatitis C Infection

First Posted Date: 2012-10-22

Last Posted Date: 2016-11-29

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 106

Registration Number: NCT01711164

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery

Not Applicable

Completed

Conditions: Cardiac Disease

Interventions: Device: Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)
Other: An alarm threshold at 75% of the baseline rSO2 value

First Posted Date: 2012-10-16

Last Posted Date: 2017-06-01

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 250

Registration Number: NCT01707446

Locations: 🇨🇦
University Heatlh Network, Toronto General Hopsital, Toronto, Ontario, Canada

The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery

Completed

Conditions: Thrombosis

First Posted Date: 2012-10-16

Last Posted Date: 2015-06-18

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 201

Registration Number: NCT01707459

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

Completed

Conditions: Colorectal Cancer
Gynecological Cancer
Breast Cancer
Metastatic
Eligible for Phase I or Phase II Study
Melanoma Cancer

First Posted Date: 2012-10-10

Last Posted Date: 2018-05-09

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 45

Registration Number: NCT01703585

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Busulfan
Drug: Melphalan
Drug: Lenalidomide

First Posted Date: 2012-10-08

Last Posted Date: 2022-09-21

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 78

Registration Number: NCT01702831

Locations: 🇨🇦
Saint John Regional Hospital, 5DN Research Department, 400 University Ave, Saint John, New Brunswick, Canada
🇨🇦
Cross Cancer Institute 11560 University Ave, Edmonton, Alberta, Canada
🇨🇦
Queen Elizabeth II Health Sciences Centre., Halifax, Nova Scotia, Canada

and more 7 locations

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose

Not Applicable

Completed

Conditions: Hyperlipidemia

Interventions: Other: Intraduodenal glucose or fructose

First Posted Date: 2012-09-27

Last Posted Date: 2015-03-10

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 14

Registration Number: NCT01694446

Locations: 🇨🇦
Toronto General Hopital, Toronto, Ontario, Canada

Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients

Completed

Conditions: Abnormalities, Radiation-Induced

First Posted Date: 2012-09-25

Last Posted Date: 2021-04-05

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 20

Registration Number: NCT01692600

Locations: 🇨🇦
Princess Margaret Hospital/UHNTorotno, Toronto, Ontario, Canada

Degarelix Neo-Adjuvant Radical Prostatectomy Trial

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Casodex
Drug: LHRH Agonist

First Posted Date: 2012-08-28

Last Posted Date: 2015-12-22

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 35

Registration Number: NCT01674270

Locations: 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: ASP7487, Velcade, Dexamethasone

First Posted Date: 2012-08-27

Last Posted Date: 2018-09-13

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 19

Registration Number: NCT01672736

Locations: 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University Of Chicago Medical Center, Chicago, Illinois, United States
🇨🇦
Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada

and more 3 locations

Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy

Phase 2

Completed

Conditions: Fatigue

Interventions: Other: Red Bull™ Sugar-Free Drink

First Posted Date: 2012-08-21

Last Posted Date: 2013-12-19

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 20

Registration Number: NCT01669460

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy